

## **Product Information Sheet for NR-19497**

# Staphylococcus aureus (MRSA), Strain COL Gateway<sup>®</sup> Clone Set, Recombinant in Escherichia coli, Plate 1

## Catalog No. NR-19497

This reagent is the tangible property of the U.S. Government.

### For research use only. Not for use in humans.

#### Contributor:

Pathogen Functional Genomics Resource Center at the J. Craig Venter Institute

#### Manufacturer:

**BEI Resources** 

#### **Product Description:**

Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g., single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources does not confirm or validate individual mutants provided by the contributor.

The methicillin-resistant *Staphylococcus aureus* (*S. aureus*), strain COL Gateway<sup>®</sup> clone set consists of 25 plates which contain 2343 sequence validated clones from *S. aureus* strain COL cloned in *Escherichia coli* (*E. coli*) DH10B-T1 cells. Each open reading frame was constructed in vector pDONR™221 with a native start codon and no stop codon. The sequence was validated by full length sequencing of each clone with greater than 1X coverage and a mutation rate of less than 0.2%. Detailed information about each clone is shown in Table 1.

Information related to the use of Gateway<sup>®</sup> Clones can be obtained from Invitrogen<sup>™</sup>. Recombination was facilitated through an attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR™221) to create an attL-containing entry clone. The entry clone contains recombinational cloning sites, attL1 and attL2 to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the Invitrogen<sup>™</sup> Gateway<sup>®</sup> Technology Manual for additional details.

Plate orientation and viability were confirmed for NR-19497.

#### **Material Provided:**

Each inoculated well of the 96-well plate contains approximately 60  $\mu$ L of culture in Luria Bertani (LB) broth containing 50  $\mu$ g/mL kanamycin supplemented with 15% glycerol.

#### Packaging/Storage:

NR-19497 was packaged aseptically in a 96-well plate. The product is provided frozen and should be stored at -80°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

#### **Growth Conditions:**

Media:

LB broth or agar containing 50 µg/mL kanamycin

Incubation:

Temperature: 37°C Atmosphere: Aerobic

Propagation:

- 1. Scrape top of frozen well with a pipette tip and streak onto
  - agar plate.
- 2. Incubate the plates at 37°C for 1 day.

#### Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Staphylococcus aureus (MRSA), Strain COL Gateway® Clone Set, Recombinant in Escherichia coli, Plate 1, NR-19497."

#### Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

#### **Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

#### **Use Restrictions:**

This material is distributed for internal research, noncommercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898



SUPPORTING INFECTIOUS DISEASE RESEARCH

## **Product Information Sheet for NR-19497**

license is required. U.S. Government contractors may need a license before first commercial sale.

ATCC<sup>®</sup> is a trademark of the American Type Culture Collection.

#### References:

 Gill, S. R., et al. "Insights on Evolution of Virulence and Resistance from the Complete Genome Analysis of an Early Methicillin-Resistant Staphylococcus aureus Strain and a Biofilm-Producing Methicillin-Resistant Staphylococcus epidermidis Strain." J. Bacteriol. 187 (2005): 2426-2438. PubMed: 15774886.

E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Product Information Sheet contains complex tables and

may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided:

Table 1: Staphylococcus aureus, Strain COL Gateway® Clones, Plate 1 (ZSAJA)¹

Clone	Well Position	ORF Length	Locus ID	Description	Accession Number	Average Depth of Coverage
1	A01	100	SACOL2693	hypothetical protein	YP 187479.1	3
5	A02	127	SACOL0039	hypothetical protein	YP 184950.1	3
7	A03	127	SACOL0057	hypothetical protein	YP 184963.1	2
10	A04	127	SACOL0393	hypothetical protein	YP 185285.1	-
11	A05	127	SACOL0561	hypothetical protein	YP 185449.1	2.976377953
15	A06	127	SACOL0852	hypothetical protein	N/A	3.960629921
19	A07	127	SACOL1953	hypothetical protein	YP 186778.1	2.992125984
23	A08	127	SACOL2372	hypothetical protein	YP 187176.1	3
25	A09	127	SACOL2640	hypothetical protein	YP 187428.1	3.992125984
27	A10	130	SACOL1027	hypothetical protein	YP 185893.1	3
29	A11	130	SACOL1156	hypothetical protein	YP 186019.1	2
31	A12	130	SACOL1237	hypothetical protein	N/A	2.976923077
35	B01	130	SACOL1463	hypothetical protein	N/A	3.9
37	B02	130	SACOL2200	hypothetical protein	YP_187011.1	4
41	B03	130	SACOL2629	hypothetical protein	YP 187418.1	3
43	B04	130	SACOL2637	hypothetical protein	YP 187425.1	3
45	B05	133	SACOL0226	hypothetical protein	N/A	4
47	B06	133	SACOL0923	hypothetical protein	N/A	1.992481203
49	B07	133	SACOL0990	hypothetical protein	YP 185858.1	3
51	B08	133	SACOL1246	hypothetical protein	YP 186106.1	3
53	B09	133	SACOL1379	hypothetical protein	YP 186232.1	1.962406015
55	B10	133	SACOL1391	hypothetical protein	N/A	3.789473684
58	B11	133	SACOL1559	hypothetical protein	YP 186400.1	2
60	B12	133	SACOL1757	hypothetical protein	YP 186591.1	1.92481203
63	C01	133	SACOL1999	conserved hypothetical protein	YP 186823.1	3
65	C02	133	SACOL2336	hypothetical protein	YP 187143.1	4
67	C03	133	SACOL2406	hypothetical protein	YP 187209.1	3
69	C04	133	SACOL2468	hypothetical protein	N/A	3.992481203
71	C05	133	SACOL2543	hypothetical protein	YP 187335.1	2
73	C06	136	SACOL0060	hypothetical protein	N/A	3.977941176
75	C07	136	SACOL0066	conserved domain protein	YP 184971.1	4
77	C08	136	SACOL0174	hypothetical protein	YP 185073.1	-
79	C09	136	SACOL0475	hypothetical protein	YP 185365.1	3.955882353
81	C10	136	SACOL0642	hypothetical protein	YP 185527.1	3
83	C11	136	SACOL1341	hypothetical protein	YP 186195.1	2
85	C12	136	SACOL1713	hypothetical protein	N/A	3
87	D01	136	SACOL1856	hypothetical protein	N/A	4
89	D02	136	SACOL2649	conserved hypothetical protein	YP 187437.1	3
91	D03	139	SACOL0133	hypothetical protein	N/A	2.985611511
96	D04	139	SACOL0817	hypothetical protein	YP 185691.1	2
97	D05	139	SACOL0866	hypothetical protein	YP 185739.1	4
99	D06	139	SACOL1050	hypothetical protein	YP 185915.1	4
101	D07	139	SACOL1336	hypothetical protein	YP 186190.1	2

BEI Resources www.beiresources.org E-mail: <a href="mailto:contact@beiresources.org">contact@beiresources.org</a>

Tel: 800-359-7370 Fax: 703-365-2898



#### SUPPORTING INFECTIOUS DISEASE RESEARCH

# **Product Information Sheet for NR-19497**

Clone	Well Position	ORF Length	Locus ID	Description	Accession Number	Average Depth of Coverage
103	D08	139	SACOL1372	hypothetical protein	YP 186225.1	1.978417266
105	D09	139	SACOL2414	conserved hypothetical protein	YP 187217.1	3.90647482
107	D10	139	SACOL2417	hypothetical protein	N/A	3
110	D11	139	SACOL2444	hypothetical protein	N/A	2
111	D12	142	SACOL0087	hypothetical protein	YP 184992.1	3
113	E01	142	SACOL0661	hypothetical protein	YP 185545.1	3.971830986
115	E02	142	SACOL0819	hypothetical protein	YP 185693.1	2.992957746
118	E03	142	SACOL1037	hypothetical protein	YP 185902.1	1.964788732
119	E04	142	SACOL1165	hypothetical protein	YP 186028.1	3
125	E05	142	SACOL2027	hypothetical protein	N/A	1.971830986
127	E06	142	SACOL2027 SACOL2139	hypothetical protein	YP 186954.1	2.584507042
129	E07	142	SACOL2139 SACOL2432	hypothetical protein	N/A	
131	E08	142	SACOL2432 SACOL2433		YP 187234.1	4
133	E09	142	SACOL2433 SACOL2595	hypothetical protein hypothetical protein	YP 187386.1	2 2
135	E10				YP 185781.1	3
		145	SACOL0910	hypothetical protein		3
137	E11	145	SACOL0933	hypothetical protein	YP_185803.1	
139	E12	145	SACOL1061	hypothetical protein	N/A	2.993103448
142	F01	145	SACOL1334	hypothetical protein	YP_186188.1	2
144	F02	145	SACOL1890	hypothetical protein	YP_186716.1	1.965517241
145	F03	145	SACOL1949	hypothetical protein	YP_186774.1	2
147	F04	145	SACOL2069	K+-transporting ATPase, F subunit	YP_186885.1	5
151	F05	145	SACOL2677	hypothetical protein	YP_187465.1	4
153	F06	148	SACOL0227	hypothetical protein	N/A	3
157	F07	148	SACOL0878	hypothetical protein	N/A	3
161	F08	148	SACOL1330	hypothetical protein	N/A	2.945945946
163	F09	148	SACOL2216	ribosomal protein L36	YP_187026.1	3
165	F10	148	SACOL2331	hypothetical protein	YP_187138.1	2.97972973
168	F11	148	SACOL2642	hypothetical protein	YP_187430.1	1.972972973
169	F12	151	SACOL0500	hypothetical protein	YP_185388.1	5
171	G01	151	SACOL1517	hypothetical protein	N/A	2
175	G02	151	SACOL1884	hypothetical protein	N/A	3.947019868
177	G03	151	SACOL2065	hypothetical protein	YP_186881.1	2.98013245
179	G04	151	SACOL2187	hypothetical protein	YP_186998.1	2.947019868
182	G05	151	SACOL2370	hypothetical protein	N/A	2
185	G06	154	SACOL0729	hypothetical protein	N/A	1.993506494
187	G07	154	SACOL1527	hypothetical protein	N/A	2
189	G08	154	SACOL1815	hypothetical protein	YP_186647.1	1.980519481
192	G09	154	SACOL2254	hypothetical protein	N/A	2
193	G10	154	SACOL2454	hypothetical protein	YP_187253.1	3
197	G11	157	SACOL0094	hypothetical protein	YP 184999.1	3
199	G12	157	SACOL0112	hypothetical protein	YP 185016.1	-
201	H01	157	SACOL0390	lipase precursor, interruption-C	YP 185282.1	2
203	H02	157	SACOL1730	hypothetical protein	N/A	2
205	H03	157	SACOL1978	hypothetical protein	YP 186802.1	2
207	H04	157	SACOL2380	hypothetical protein	YP 187184.1	-
209	H05	157	SACOL2489	conserved hypothetical protein	YP 187285.1	2
211	H06	157	SACOL2492	hypothetical protein	YP_187287.1	2
213	H07	157	SACOL2510	hypothetical protein	YP 187305.1	2
215	H08	160	SACOL0223	hypothetical protein	YP 185121.1	2
217	H09	160	SACOL1258	hypothetical protein	N/A	-
221	H10	160	SACOL1508	hypothetical protein	YP 186352.1	_
223	H11	160	SACOL2032	hypothetical protein	N/A	3
225	H12	160	SACOL2191	hypothetical protein	YP 187002.1	-
	1112	100	_ 5, (OOLZ 101	Trypotriotion protein	11_107002.1	1

<sup>&</sup>lt;sup>1</sup>All information in this table was provided by the J. Craig Venter Institute at the time of deposition.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898